Experience

PBM Capital Group

• United States
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• SVP Business Development & Portfolio Management

  • Mar 2014 - Present

  • Part of Executive leadership team evaluating new business investment opportunities • Provide technical and strategic support to internal development programs • Liaise and work closely with key portfolio investment companies to advance their product candidates • Program lead for multiple internal programs ranging from small-molecule to biologics and gene therapy



Pavilion XI Partners, LLC

• President

  • Sep 2013 - Present

  • Provide broad strategic business and technical consulting services • Conduct business and technical contract diligence efforts supporting both decisions to invest as well as to pass on investment opportunities • Board Member and senior advisor to Blue Prairie Brands, LLC Company develops wholesome, functional, high fiber ingredients for the food industry



Intrexon Corporation

• United States
• Biotechnology
• 1 - 100 Employee

• President, Human Therapeutics Division (HTD), Corporate Senior Vice-President

  • Jan 2012 - Aug 2013

  Germantown, MD • Part of Executive leadership team during which time >$400 million in proceeds were raised through Series E and F financings and an IPO with a $1.6B pre-money valuation • Led diverse team responsible for translational research, medicinal chemistry, CMC (small molecule and biologics programs), vivarium operations, project management and alliance management • Restructured division (including hiring of key new employees and elimination of certain roles) to improve performance and… Show more • Part of Executive leadership team during which time >$400 million in proceeds were raised through Series E and F financings and an IPO with a $1.6B pre-money valuation • Led diverse team responsible for translational research, medicinal chemistry, CMC (small molecule and biologics programs), vivarium operations, project management and alliance management • Restructured division (including hiring of key new employees and elimination of certain roles) to improve performance and productivity, reduce costs, and significantly increase revenue • Created highly collaborative environment between HTD and other Intrexon Divisions for improved efficiency and data generation • Principal point of contact for multiple partnered programs in oncology, dermatology and other Rare/Orphan diseases • Drove progression of business development opportunities and establishment of new partnerships • Generation of >$30 million in revenue through multiple licensing/partnership transactions (established 4 new partnerships) and achievement of a Phase II development milestone for partnered oncology product Show less



Forest Laboratories

• Austria
• Medical Practices

• Vice President, Research and Virginia Operations

  • Apr 2011 - Jan 2012

  Charlottesville, Virginia Area *CLDA was acquired by Forest in April, 2011. Forest closed the Virginia facility in December, 2011. • Maintained all responsibilities from Clinical Data prior to acquisition and assumed additional management roles • Point person for integration planning and portfolio transfer with Forest for Virginia-based facilities and programs • Project Team Leader for progression from IND to Clinical Studies for diabetes/asthma program • Led advancement of key ophthalmic program to… Show more *CLDA was acquired by Forest in April, 2011. Forest closed the Virginia facility in December, 2011. • Maintained all responsibilities from Clinical Data prior to acquisition and assumed additional management roles • Point person for integration planning and portfolio transfer with Forest for Virginia-based facilities and programs • Project Team Leader for progression from IND to Clinical Studies for diabetes/asthma program • Led advancement of key ophthalmic program to human POC studies with strategic partner Santen Show less



Clinical Data

• Vice President, Research and Virginia Operations

  • Aug 2008 - Apr 2011

  Charlottesville, Virginia Area *Adenosine Therapeutics was acquired by CLDA in August, 2008 Vice-President, Research and Virginia Operations (April 2010 – April 2011) Vice-President, Research (April 2009- April 2010) Vice-President, Lead Development (August 2008- April 2009) • Oversight of all Virginia operations (administrative, medicinal chemistry, pharmacology, pre-clinical development through Phase I studies) • Managed and oversaw Research and Operations budget >$10M and twenty research and… Show more *Adenosine Therapeutics was acquired by CLDA in August, 2008 Vice-President, Research and Virginia Operations (April 2010 – April 2011) Vice-President, Research (April 2009- April 2010) Vice-President, Lead Development (August 2008- April 2009) • Oversight of all Virginia operations (administrative, medicinal chemistry, pharmacology, pre-clinical development through Phase I studies) • Managed and oversaw Research and Operations budget >$10M and twenty research and administrative personnel • Key Business Manager and Technical Contact for Major Company Relationships • Santen Pharmaceuticals (leading Japanese ophthalmic company) • Zalicus (NSDQ: ZLCS, formerly CombinatoRx) • Novartis Pharmaceuticals • Confidential Major Drug-Device Company • University of Virginia • University of Colorado, Boulder • >100 other academic/corporate MTAs and collaborations Show less



Adenosine Therapeutics, LLC

• Vice President, Lead Development

  • Jul 2002 - Aug 2008

  Charlottesville, Virginia Area Vice-President, Lead Development (April 2008-August 2008) Director, Lead Development (April 2007-April 2008) Program Manager (January 2005- April 2007) Group Leader, Medicinal Chemistry (July 2002- January 2005) • Invented and developed novel compounds for key inflammation programs • Co-inventor on more than fifteen company composition of matter and method patents • Multiple lead compounds identified and synthesized • Two compounds nominated for IND candidacy and formal… Show more Vice-President, Lead Development (April 2008-August 2008) Director, Lead Development (April 2007-April 2008) Program Manager (January 2005- April 2007) Group Leader, Medicinal Chemistry (July 2002- January 2005) • Invented and developed novel compounds for key inflammation programs • Co-inventor on more than fifteen company composition of matter and method patents • Multiple lead compounds identified and synthesized • Two compounds nominated for IND candidacy and formal development • Ran company’s computational and metabolism departments • Consulted on analytical and CMC support for clinical development • Managed and reviewed company patent portfolio of over fifty issued/pending patents. • After hiring of full-time patent counsel in 2006, assisted with drafting and patent strategy • Principal or Co-investigator for robust grant program, wrote and reviewed over twenty NIH grant applications resulting in over $10 million of direct company funding and more than a dozen awarded grants Show less